<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04046172</url>
  </required_header>
  <id_info>
    <org_study_id>123436</org_study_id>
    <nct_id>NCT04046172</nct_id>
  </id_info>
  <brief_title>Treatment of Periodontal Disease in Systemic Lupus Erythematosus</brief_title>
  <official_title>Treatment of Periodontal Disease in Systemic Lupus Erytematosus: A Pilot Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many studies have conducted to evaluate the relationship of systemic inflammatory diseases
      with periodontal disease. Previous evaluations suggest that there is no significant
      association between patients with Systemic lupus erythematosus (SLE) and Periodontitis (PD).
      However, some of the studies have shown relevancy between these two inflammatory diseases and
      have suggested to explore more for further knowledge. The aim of the study is to establish
      and investigate a relationship between SLE and PD. The study which will take place in two
      centers and will recruit 30 patients which will enter a pilot randomized controlled trial.
      Individuals enrolled into the study will be randomly assigned to the test or control group in
      a 1:1 ratio. Study will be divided in to six visits for the patients and the length of the
      study will be of 6 months. Visit 1 will be consisting of Screening including consent and
      Periodontal examination of the patients. Visit 2 includes orthopantomogram (OPG),
      Comprehensive periodontal examination recording, Blood samples collection vascular function
      assessment and optical coherence tomography (OCT). Intensive periodontal treatment (IPT) for
      test group and control periodontal treatment (CPT) for control group including medical
      history recording according to group allocation in visit 3 for control group and (3a and 3b)
      for test group will take place. Follow ups after two months will be conducted in Visit 4 for
      both groups including Demographics, medical history and concomitant medications recording,
      comprehensive periodontal examination recording, OCT, blood samples/saliva samples collection
      and vascular function assessment. Visit 3 and 5 will be conducted as periodontal treatment
      (IPT for test group and CPT for the control group), medical history recording, including
      demographics, Alogrithm for cardiovascular disease (Qrisk3) questionnaire (Visit 3 only) to
      assess the cardio-vascular risk medical history and concomitant medications recording,
      comprehensive periodontal examination recording, blood samples collection and vascular
      function assessment. Last visit will be 6 months follow up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a pilot trial that will take place in a multi-center where participants will be
      randomly allocated to one of two groups (control and test group). Each participant in test
      group will attend 7 visits (screening, baseline, periodontal treatment visit (Visit 3a and
      3b), 2-month follow-up, second periodontal treatment and 6-months Follow-up visit). In the
      control group each participant will attend 6 visits (Screening, baseline, periodontal
      treatment visit, 2-months follow-up visit, second periodontal treatment visit and 6-months
      follow-up). The study will recruit 15 participants per group (30 participants total).
      Potential participants will be provided with an information sheet (if interested) will attend
      a screening visit to confirm eligibility for inclusion in the study. Written informed consent
      will be obtained and the baseline visit will be scheduled. Following enrollment, the study
      will require attendance at 6 visits for the control and 7 visits (visit 3a and 3b) for test
      groups. Participant would be asked at screening and blood would be collected on the same day
      of the Baseline Visit and Flow mediated dilatation (FMD) will also take place at the baseline
      visit. Below is a summary of measures and procedures that will take place at each visit:

      Visit 1 Screening Visit - Day 0 (30 minutes): Potential participants will have the
      opportunity to ask questions to the study staff. If they wish to take part, participants will
      be asked to sign three copies of the consent form. One copy will be kept by the research
      centre and the other copy, along with a copy of the information sheet, will be given to them
      and the third copy of the consent form will be kept in the medical records. Investigator will
      ask some questions about their medical history and examine their mouth to confirm eligibility
      for participation in this study. Any changes in their health history will be noted in each
      visit. Height, weight, and blood pressure will be measured. In visit 2 there will be a sample
      of their blood and saliva/plaque and will be collected in three of the visits OPG and OCT
      will be done in the 2nd visit. Following this, a score of the amount of plaque on their teeth
      and some measurements of their gum health will be recorded. Visit 3 (a and b) will be
      assigned only for the test group in which they will be provided with the Intensive
      periodontal treatment (IPT). Control group will also undergo through (Control periodontal
      treatment/CPT) in their visit 3. Visit 4 will be a two-month follow-up for the test and the
      control group in which they will undergo from periodontal assessment, flow mediated
      dilatation, collection of blood samples and optical coherence tomography (OCT). Visit 5 is
      for the control and test group in which they will undergo the second periodontal treatment
      (IPT and CPT). 6-months follow up will consist of Flow mediated dilatation, periodontal
      assessment collection of blood samples and Optical coherence tomography (OCT) for both the
      groups. Study completion will take place after 6 months of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Total 30 Participants. Test group (n=15) control group (n=15)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>It is a single-blinded study in which cardio-vascular technician will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To measure the effect of periodontal treatment on SLE patients</measure>
    <time_frame>2 years</time_frame>
    <description>Endothelial function/dysfunction (vessel wall elasticity) will be observed in the population of SLE patients (30) who will undergo periodontal treatment (before and after) by using Flow mediated dilatation (FMD) which is an ultra-sound scan of brachial artery in visit 2, 4 and 6).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure the effect of PT on biomarkers of SLE disease severity/progression in a population of patients suffering from SLE and PD.</measure>
    <time_frame>2 years</time_frame>
    <description>30 Patients will be recruited and will run a blood test in visit 2, 4 and 6 to observe the CRP (C-reactive Protein) that is an inflammatory marker before and after Periodontal treatment in patients with SLE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the effect of Periodontal Treatment on the B-cell panel in a population of patients suffering from SLE and PD.</measure>
    <time_frame>2 Years</time_frame>
    <description>Since B-cells (lymphocytes) are already unnaturally high in SLE patients we want to see if Periodontal Treatment decreases the total cell load/population by Flow cytometry with the blood samples taken form the (30) SLE patients in visit 2, 4 and 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the effect of Periodontal Treatment on the systemic inflammatory and oxidative profile of a population of patients suffering from SLE and PD.</measure>
    <time_frame>2 years</time_frame>
    <description>Because SLE and Periodontal diseases are both chronic inflammatory diseases Nitrous oxide production is raised in both diseases leading to self inflicted tissue damage. Blood will be drawn form the (30) patients with SLE and will run a D-ROM test on the blood samples taken in visit 2, 4 and 6 to observe the oxidative profile of the patients with SLE before and after periodontal treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the effect of Periodontal Treatment on skin lesions in a population of patients suffering from SLE and PD.</measure>
    <time_frame>2 years</time_frame>
    <description>30 SLE patients will undergo OCT (Optical coherence tomography) investigation. SLE patients might have skin lesion as an immune destructive response by the cells. OCT will observe the skin lesions caused by the disease (SLE) in visit 2, 4 and 6 (before and after periodontal treatment)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Periodontitis</condition>
  <arm_group>
    <arm_group_label>test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intensive periodontal treatment (IPT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Control periodontal treatment (CPT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>supra/sub gingival root surface debridement</intervention_name>
    <description>The test group will undergo Intensive periodontal treatment (IPT)</description>
    <arm_group_label>test group</arm_group_label>
    <other_name>IPT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>supra-gingival scaling and polishing</intervention_name>
    <description>Control group will receive the Control periodontal treatment (CPT).</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>CPT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male/Female Subject must be 18 years of age or over.

          2. Patients with 4 or more criteria for juvenile systemic lupus erythematosus (JSLE) or
             SLE according to the American College of Rheumatology (ACR) 1997 criteria or SLICC
             2012 criteria or biopsy proven lupus nephritis with one additional supportive test on
             at least two occasions (positive Anti-nuclear antibodies (ANA), anti-dsDNA antibodies
             or anti-Sm antibodies).

          3. Presence of moderate to severe periodontitis (at least 30 pockets with Probing depth
             equal or greater than 5mm).

          4. Subject must have voluntarily signed the informed consent.

        Exclusion Criteria:

          1. Pregnancy or breastfeeding.

          2. Having fewer than 15 teeth.

          3. Subject knowingly has HIV or Hepatitis.

          4. Subject is not capable to give informed consent.

          5. Presence of concomitant rheumatoid arthritis, Sjogren syndrome, diabetes mellitus.

          6. Smoking.

          7. Subject on anticoagulants.

          8. Subjects on chronic antibiotic therapy or who require antibiotic coverage for
             periodontal procedures.

          9. Subjects who received periodontal treatment within 6 months from the baseline

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco D`Aiuto, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Unit of Periodontology Eastman Dental Institute,UCL.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Coziana Ciurtin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Rheumatology, UCLH.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Orlandi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Unit of Periodontology Eastman Dental Institute,UCL.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacopo Buti, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Unit of Periodontology Eastman Dental Institute,UCL.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Syed Basit Hussain, BDS</last_name>
    <phone>+447477024924</phone>
    <email>syed.hussain.16@ucl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eastman clinical investigation centre (ECIC) Eastman Dental Institute.</name>
      <address>
        <city>London</city>
        <zip>wc1 x8ld</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Jacobsen S, Petersen J, Ullman S, Junker P, Voss A, Rasmussen JM, Tarp U, Poulsen LH, van Overeem Hansen G, Skaarup B, Hansen TM, Pødenphant J, Halberg P. A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value. Clin Rheumatol. 1998;17(6):478-84.</citation>
    <PMID>9890675</PMID>
  </reference>
  <reference>
    <citation>Bartels CM, Buhr KA, Goldberg JW, Bell CL, Visekruna M, Nekkanti S, Greenlee RT. Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol. 2014 Apr;41(4):680-7. doi: 10.3899/jrheum.130874. Epub 2014 Feb 15.</citation>
    <PMID>24532834</PMID>
  </reference>
  <reference>
    <citation>Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976 Feb;60(2):221-5.</citation>
    <PMID>1251849</PMID>
  </reference>
  <reference>
    <citation>Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejía JC, Aydintug AO, Chwalinska-Sadowska H, de Ramón E, Fernández-Nebro A, Galeazzi M, Valen M, Mathieu A, Houssiau F, Caro N, Alba P, Ramos-Casals M, Ingelmo M, Hughes GR; European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003 Sep;82(5):299-308.</citation>
    <PMID>14530779</PMID>
  </reference>
  <reference>
    <citation>Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, Atzeni F, Piccoli A, Todesco S. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006 Aug;119(8):700-6.</citation>
    <PMID>16887417</PMID>
  </reference>
  <reference>
    <citation>Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997 Mar 1;145(5):408-15.</citation>
    <PMID>9048514</PMID>
  </reference>
  <reference>
    <citation>Skamra C, Ramsey-Goldman R. Management of cardiovascular complications in systemic lupus erythematosus. Int J Clin Rheumtol. 2010 Feb 1;5(1):75-100.</citation>
    <PMID>20305727</PMID>
  </reference>
  <reference>
    <citation>Bruce IN, Gladman DD, Urowitz MB. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am. 2000 May;26(2):257-78. Review.</citation>
    <PMID>10768212</PMID>
  </reference>
  <reference>
    <citation>Salmon JE, Roman MJ. Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management. Curr Opin Rheumatol. 2001 Sep;13(5):341-4. Review.</citation>
    <PMID>11604586</PMID>
  </reference>
  <reference>
    <citation>Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003 Dec 18;349(25):2407-15.</citation>
    <PMID>14681506</PMID>
  </reference>
  <reference>
    <citation>Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, Gilburd B, Corbanese S, Patnaik M, Zampieri S, Peter JB, Favaretto E, Iaccarino L, Sherer Y, Todesco S, Pauletto P. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2003 Nov;62(11):1071-7.</citation>
    <PMID>14583570</PMID>
  </reference>
  <reference>
    <citation>Korkmaz H, Onalan O. Evaluation of endothelial dysfunction: flow-mediated dilation. Endothelium. 2008 Jul-Aug;15(4):157-63. doi: 10.1080/10623320802228872. Review.</citation>
    <PMID>18663619</PMID>
  </reference>
  <reference>
    <citation>Inoue T, Node K. Vascular failure: A new clinical entity for vascular disease. J Hypertens. 2006 Nov;24(11):2121-30. Review.</citation>
    <PMID>17053528</PMID>
  </reference>
  <reference>
    <citation>Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002 Aug 6;106(6):653-8.</citation>
    <PMID>12163423</PMID>
  </reference>
  <reference>
    <citation>Matsuzawa Y, Lerman A. Endothelial dysfunction and coronary artery disease: assessment, prognosis, and treatment. Coron Artery Dis. 2014 Dec;25(8):713-24. doi: 10.1097/MCA.0000000000000178. Review.</citation>
    <PMID>25365643</PMID>
  </reference>
  <reference>
    <citation>Liao JK, Bettmann MA, Sandor T, Tucker JI, Coleman SM, Creager MA. Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res. 1991 Apr;68(4):1027-34.</citation>
    <PMID>2009605</PMID>
  </reference>
  <reference>
    <citation>Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis. 1997 Jan-Feb;39(4):287-324. Review.</citation>
    <PMID>9050817</PMID>
  </reference>
  <reference>
    <citation>Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992 Nov 7;340(8828):1111-5.</citation>
    <PMID>1359209</PMID>
  </reference>
  <reference>
    <citation>Piper MK, Raza K, Nuttall SL, Stevens R, Toescu V, Heaton S, Gardner-Medwin J, Hiller L, Martin U, Townend J, Bacon PA, Gordon C. Impaired endothelial function in systemic lupus erythematosus. Lupus. 2007;16(2):84-8.</citation>
    <PMID>17402363</PMID>
  </reference>
  <reference>
    <citation>Mak A, Kow NY, Schwarz H, Gong L, Tay SH, Ling LH. Endothelial dysfunction in systemic lupus erythematosus - a case-control study and an updated meta-analysis and meta-regression. Sci Rep. 2017 Aug 4;7(1):7320. doi: 10.1038/s41598-017-07574-1.</citation>
    <PMID>28779080</PMID>
  </reference>
  <reference>
    <citation>Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009 Dec 1;54(23):2129-38. doi: 10.1016/j.jacc.2009.09.009. Review.</citation>
    <PMID>19942084</PMID>
  </reference>
  <reference>
    <citation>Petersen PE, Bourgeois D, Ogawa H, Estupinan-Day S, Ndiaye C. The global burden of oral diseases and risks to oral health. Bull World Health Organ. 2005 Sep;83(9):661-9. Epub 2005 Sep 30.</citation>
    <PMID>16211157</PMID>
  </reference>
  <reference>
    <citation>Albandar JM, Rams TE. Global epidemiology of periodontal diseases: an overview. Periodontol 2000. 2002;29:7-10.</citation>
    <PMID>12102700</PMID>
  </reference>
  <reference>
    <citation>D'Aiuto F, Graziani F, Tetè S, Gabriele M, Tonetti MS. Periodontitis: from local infection to systemic diseases. Int J Immunopathol Pharmacol. 2005 Jul-Sep;18(3 Suppl):1-11. Review.</citation>
    <PMID>16848982</PMID>
  </reference>
  <reference>
    <citation>Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E. Periodontal infections contribute to elevated systemic C-reactive protein level. J Periodontol. 2001 Sep;72(9):1221-7.</citation>
    <PMID>11577954</PMID>
  </reference>
  <reference>
    <citation>D'Aiuto F, Orlandi M, Gunsolley JC. Evidence that periodontal treatment improves biomarkers and CVD outcomes. J Periodontol. 2013 Apr;84(4 Suppl):S85-S105. doi: 10.1902/jop.2013.134007. Review.</citation>
    <PMID>23631587</PMID>
  </reference>
  <reference>
    <citation>Orlandi M, Suvan J, Petrie A, Donos N, Masi S, Hingorani A, Deanfield J, D'Aiuto F. Association between periodontal disease and its treatment, flow-mediated dilatation and carotid intima-media thickness: a systematic review and meta-analysis. Atherosclerosis. 2014 Sep;236(1):39-46. doi: 10.1016/j.atherosclerosis.2014.06.002. Epub 2014 Jun 17. Review.</citation>
    <PMID>25014033</PMID>
  </reference>
  <reference>
    <citation>D'Aiuto F, Nibali L, Parkar M, Patel K, Suvan J, Donos N. Oxidative stress, systemic inflammation, and severe periodontitis. J Dent Res. 2010 Nov;89(11):1241-6. doi: 10.1177/0022034510375830. Epub 2010 Aug 25.</citation>
    <PMID>20739696</PMID>
  </reference>
  <reference>
    <citation>Tonetti MS, D'Aiuto F, Nibali L, Donald A, Storry C, Parkar M, Suvan J, Hingorani AD, Vallance P, Deanfield J. Treatment of periodontitis and endothelial function. N Engl J Med. 2007 Mar 1;356(9):911-20. Erratum in: N Engl J Med. 2018 Jun 13;:null.</citation>
    <PMID>17329698</PMID>
  </reference>
  <reference>
    <citation>de Pablo P, Dietrich T, McAlindon TE. Association of periodontal disease and tooth loss with rheumatoid arthritis in the US population. J Rheumatol. 2008 Jan;35(1):70-6. Epub 2007 Nov 15.</citation>
    <PMID>18050377</PMID>
  </reference>
  <reference>
    <citation>Calderaro DC, Ferreira GA, de Mendonça SM, Corrêa JD, Santos FX, Sanção JG, da Silva TA, Teixeira AL. Is there an association between systemic lupus erythematosus and periodontal disease? Rev Bras Reumatol Engl Ed. 2016 May-Jun;56(3):280-4. doi: 10.1016/j.rbre.2015.08.003. Epub 2015 Sep 8. English, Portuguese.</citation>
    <PMID>27267648</PMID>
  </reference>
  <reference>
    <citation>Rutter-Locher Z, Smith TO, Giles I, Sofat N. Association between Systemic Lupus Erythematosus and Periodontitis: A Systematic Review and Meta-analysis. Front Immunol. 2017 Oct 17;8:1295. doi: 10.3389/fimmu.2017.01295. eCollection 2017.</citation>
    <PMID>29089946</PMID>
  </reference>
  <reference>
    <citation>Rydén L, Buhlin K, Ekstrand E, de Faire U, Gustafsson A, Holmer J, Kjellström B, Lindahl B, Norhammar A, Nygren Å, Näsman P, Rathnayake N, Svenungsson E, Klinge B. Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the PAROKRANK Study. Circulation. 2016 Feb 9;133(6):576-83. doi: 10.1161/CIRCULATIONAHA.115.020324. Epub 2016 Jan 13.</citation>
    <PMID>26762521</PMID>
  </reference>
  <reference>
    <citation>Fabbri C, Fuller R, Bonfá E, Guedes LK, D'Alleva PS, Borba EF. Periodontitis treatment improves systemic lupus erythematosus response to immunosuppressive therapy. Clin Rheumatol. 2014 Apr;33(4):505-9. doi: 10.1007/s10067-013-2473-2. Epub 2014 Jan 11.</citation>
    <PMID>24415114</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 15, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <last_update_submitted>August 2, 2019</last_update_submitted>
  <last_update_submitted_qc>August 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Periodontitis</keyword>
  <keyword>SLE</keyword>
  <keyword>Lupus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Periodontal Diseases</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

